Trending Now
CRISPR Therapeutics (NASDAQ:CRSP) Announce Positive Phase 1 CARBON study Results Of...
CRISPR Therapeutics (NASDAQ:CRSP) has released encouraging top-line results from its ongoing Phase 1 CARBON study. The study evaluates the efficacy and safety of its...
DIH Holding US, Inc. (DHAI): Pioneering Rehabilitation with Cutting-Edge Technology
Let’s talk about something truly inspiring: the future of rehabilitation. On December 23, 2024, DIH Holding US, Inc. (NASDAQ: DHAI) announced...
Predictive Oncology Inc. (Nasdaq: POAI): A Transformative Acquisition by Renovaro Inc.
The biotechnological domain is currently abuzz with developments surrounding the acquisition of Predictive Oncology Inc. (Nasdaq: POAI) by Renovaro Inc. (Nasdaq: RENB)....
Popular News
Anavex Life Sciences Corp (NASDAQ:AVXL) Surpass Enrolment Target By 50% in...
Anavex Life Sciences Corp (NASDAQ:AVXL) has announced that it has exceeded its ANAVEX®2-73 (blarcamesine) second Phase study in Rett syndrome enrolment target by 50%....
MAKE IT MODERN
LATEST REVIEWS
Senti Biosciences, Inc. (SNTI) could keep surging and here’s why
Senti Biosciences, Inc. (Nasdaq: SNTI), a trailblazer in the biotechnology industry, has recently grabbed headlines with its remarkable stock performance and innovative...
MAKE IT MODERN
PERFORMANCE TRAINING
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) Announce Positive PHALCON-EE Study Results Of Vonoprazan in Erosive...
Phathom Pharmaceuticals Inc. (NASDAQ: PHAT) announced that vonoprazan met the primary endpoints and core secondary superiority endpoints in PHALCON-EE, a vital third phase study...
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) Releases Cohort 4 C-144-01 Study Data In Advanced Melanoma
Iovance Biotherapeutics Inc. (NASDAQ:IOVA) has announced preliminary data from vital Cohort 4 as well as updated Cohort 2 data in its C-144-01 lifileucel study...
Capricor Therapeutics Inc (NASDAQ: CAPR) Announces That Study Indicates Safety of CAP-1002
Capricor Therapeutics Inc (NASDAQ: CAPR) has found that its study on CAP-1002 is safe. This announcement comes after a Phase II trial to evaluate...
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) Doses Its First Patient in the LTX-315 Trial
Verrica Pharmaceuticals Inc (NASDAQ: VRCA) has dosed its first patients in the LTX-315 Phase II study. The company developed the drug to treat basal...
Big News Is Accelerating This Small Cap Biotech
With an FDA-approved, non-opioid drug in commercial production, a revolutionary chemotherapy alternative in pre-clinical trials, and a potential COVID therapeutic in the works, Q BioMed (OTC:...
MAKE IT MODERN
